Overall rank by patents
#42,207
Across all tracked assignees
USPTO PatentsView assignee record - 6 granted patents across 4 technology areas, active 2016–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C12M (APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERME).
The verdict
PBS holds 6 US patents across 4 technology areas, rank #42,207 of 50,000 tracked assignees.
PBS Biotech, Inc. has been granted 6 US utility patents between 2016 and 2025, placing PBS Biotech, Inc. at rank #42,207 across all assignees tracked by PlainPatent. This portfolio spans 4 distinct Cooperative Patent Classification (CPC) subclasses, averaging 21.0 claims per patent with primary concentration in C12M (APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERME). As a US Corporation, PBS Biotech, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, PBS sits between Pathoquest (6 patents, rank #42,203) and Pedigo Products, Inc. (6 patents, rank #42,211) - the closest US assignees by grant volume. The composite Innovation Score of 26.4/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 1 grants, compared with 5 in the 2015–2019 window, a -80% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. PBS Biotech, Inc.'s 21.0 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while specialization in 4 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark PBS Biotech, Inc. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
PATHOQUEST
6 patents
PATIENTS PENDING LTD.
6 patents
PAUA TRADING LIMITED
6 patents
PBM Nutritionals, LLC
6 patents
PCMR International Ltd.
6 patents
PDS IG Holdings LLC
6 patents
PDX Pharmaceuticals, Inc.
6 patents
PEDIGO PRODUCTS, INC.
6 patents
PBS BIOTECH, INC.
6 patents
What this shows PBS holds 6 patents at rank #42,207, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #42,207 in granted patent volume.
Other assignees with the most granted patents in PBS's primary technology class.
PBS's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
26 Top 80% higher than 20% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2016 | 1 | 16.7% |
| 2017 | 1 | 16.7% |
| 2018 | 2 | 33.3% |
| 2019 | 1 | 16.7% |
| 2025 | 1 | 16.7% |
Top 4 of 4 technology areas
Overall rank by patents
#42,207
Across all tracked assignees
26.4 out of 100
How to use this portfolio
PBS's 6 grants land it in the top 80% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.